Analysis Provides Insight Into FDA's Biosimilars Workload
This article was originally published in Scrip
Executive Summary
A final analysis of the first three years of the first round of the Biosimilar User Fee Act (BsUFA) found the FDA spent $81.7m on biosimilars-related work.